Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

862 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of linagliptin vs. voglibose on daily glucose excursions during continuous glucose monitoring of Japanese type 2 diabetes patients (L-CGM): A randomized, open-label, two-arm, parallel comparative trial.
Satoh H, Ohira T, Moriya C, Inoue I, Kuribayashi S, Seino H, Hirai H, Hiyoshi T, Watada H; L-CGM Study Group. Satoh H, et al. Among authors: inoue i. Diabetes Metab. 2017 Dec;43(6):550-553. doi: 10.1016/j.diabet.2017.07.010. Epub 2017 Sep 22. Diabetes Metab. 2017. PMID: 28947255 Clinical Trial. No abstract available.
Effects of linagliptin monotherapy compared with voglibose on postprandial lipid profiles in Japanese patients with type 2 diabetes: linagliptin study of effects on postprandial blood glucose (L-STEP) sub-study 1.
Kurozumi A, Okada Y, Satoh H, Inoue I, Chimori H, Akita E, Shiraiwa T, Fujitani Y, Mita T, Gosho M, Watada H. Kurozumi A, et al. Among authors: inoue i. Endocr J. 2018 Apr 26;65(4):415-425. doi: 10.1507/endocrj.EJ17-0386. Epub 2018 Jan 25. Endocr J. 2018. PMID: 29367471 Free article. Clinical Trial.
Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
Fuchigami A, Shigiyama F, Kitazawa T, Okada Y, Ichijo T, Higa M, Hiyoshi T, Inoue I, Iso K, Yoshii H, Hirose T, Kumashiro N. Fuchigami A, et al. Among authors: inoue i. Cardiovasc Diabetol. 2020 Jan 7;19(1):1. doi: 10.1186/s12933-019-0977-z. Cardiovasc Diabetol. 2020. PMID: 31910850 Free PMC article. Clinical Trial.
Intrinsic insulin secretion capacity might be preserved by discontinuing anti-programmed cell death protein 1 antibody treatment in 'anti-programmed cell death protein 1 antibody-induced' fulminant type 1 diabetes.
Sakai G, Saito D, Nakajima R, Hatano M, Noguchi Y, Kurihara S, Katayama S, Inoue I, Noda M, Shimada A. Sakai G, et al. Among authors: inoue i. J Diabetes Investig. 2018 Mar;9(2):448-449. doi: 10.1111/jdi.12662. J Diabetes Investig. 2018. PMID: 29504279 Free PMC article.
862 results